Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Chief Discovery Officer | February 12, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tyra Biosciences, Inc.
Report date February 12, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,981 |
Ending reported balance
After 2026-02-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-12 · Sale · Disposed 2,128 · Balance 152,853 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $31.02 to $31.75. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Row 2 · 2026-02-12 · Sale · Disposed 5,872 · Balance 146,981 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $32.98 to $33.85. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.
F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $31.02 to $31.75. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $32.98 to $33.85. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2023 Filed Mar 29, 2023 23:53 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 8,048 | $0.61 | $4,909.28 |
DisclosureSEC source: 0001209191-23-021564 · doc4.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2023 Filed Mar 23, 2023 23:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,827 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-020846 · doc4.xml · derivative · entry 9 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,402 Underlying: Common Stock · 4,827 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| March 23, 2023 Filed Mar 23, 2023 23:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 4,827 | $16.00 | $77,232.00 |
DisclosureSEC source: 0001209191-23-020846 · doc4.xml · nonDerivative · entry 6 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 23, 2023 Filed Mar 23, 2023 23:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 4,827 | $0.61 | $2,944.47 |
DisclosureSEC source: 0001209191-23-020846 · doc4.xml · nonDerivative · entry 5 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 532,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 23:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,800 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-020846 · doc4.xml · derivative · entry 8 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,229 Underlying: Common Stock · 3,800 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 23:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 3,800 | $16.00 | $60,800.00 |
DisclosureSEC source: 0001209191-23-020846 · doc4.xml · nonDerivative · entry 4 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 23:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 3,800 | $0.61 | $2,318.00 |
DisclosureSEC source: 0001209191-23-020846 · doc4.xml · nonDerivative · entry 3 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 531,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 23:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,100 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-020846 · doc4.xml · derivative · entry 7 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,029 Underlying: Common Stock · 14,100 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 23:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 14,100 | $16.00 | $225,600.00 |
DisclosureSEC source: 0001209191-23-020846 · doc4.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 23:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 14,100 | $0.61 | $8,601.00 |
DisclosureSEC source: 0001209191-23-020846 · doc4.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 542,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 21:36 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 249,532 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001209191-22-049212 · doc4.xml · derivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,532 Underlying: Common Stock · 249,532 shares Expires 2032-09-05 F2 · derivative.exercise_date: 1/36th of the shares subject to the option vest monthly following September 6, 2022, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 21:36 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001209191-22-049212 · doc4.xml · derivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2032-09-05 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following September 6, 2022, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:42 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 7,964 | $0.00 Strike: $24.15 | $0.00 |
DisclosureSEC source: 0001209191-21-063012 · doc4.xml · derivative · entry 3 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,964 Underlying: Common Stock · 7,964 shares Expires 2031-11-01 F2 · derivative.exercise_date: The option vests based on achievement of a performance objective. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:42 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 7,964 | $0.00 Strike: $24.15 | $0.00 |
DisclosureSEC source: 0001209191-21-063012 · doc4.xml · derivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,964 Underlying: Common Stock · 7,964 shares Expires 2031-11-01 F2 · derivative.exercise_date: The option vests based on achievement of a performance objective. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:42 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 83,626 | $0.00 Strike: $24.15 | $0.00 |
DisclosureSEC source: 0001209191-21-063012 · doc4.xml · derivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,626 Underlying: Common Stock · 83,626 shares Expires 2031-11-01 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following November 2, 2021, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:48 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries A Preferred Stock · Derivative | 3,273 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036432 · doc4.xml · derivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,501 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:48 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionCommon Stock | 8,501 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036432 · doc4.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.